Erdafixen 4 mg (Erdafitinib) Tablets

Erdafixen (Erdafitinib) 4 mg Tablets is a targeted anticancer medicine designed to block abnormal Fibroblast Growth Factor Receptor (FGFR) signaling involved in the growth and spread of certain cancer cells. It is primarily prescribed for adults with locally advanced or metastatic urothelial carcinoma (bladder cancer) that carries susceptible FGFR2 or FGFR3 genetic alterations, confirmed through an approved diagnostic test.

Therapeutic Uses

• Treatment of locally advanced urothelial carcinoma with FGFR alterations.
• Management of metastatic bladder cancer after progression on platinum-based chemotherapy.
• Targeted therapy for patients who are eligible for FGFR inhibitor treatment.
• Helps slow tumor growth and reduce cancer progression by inhibiting abnormal FGFR activity.
• May improve disease control and progression-free survival in appropriately selected patients.
• Used under the supervision of an experienced oncology specialist as part of a personalized cancer treatment plan.

Therapeutic Effects

• Blocks abnormal FGFR signaling pathways.
• Inhibits cancer cell proliferation.
• Reduces tumor growth and spread.
• Supports targeted treatment based on tumor genetic profiling.
• Helps improve clinical outcomes in eligible patients with FGFR-positive urothelial carcinoma.

Each film-coated tablet contains:

• Active Ingredient: Erdafitinib 4 mg

Pharmacological Class

• Fibroblast Growth Factor Receptor (FGFR) Inhibitor
• Targeted Anticancer Agent
• Oral Tyrosine Kinase Inhibitor

The formulation also contains pharmaceutical excipients required for tablet stability, coating, and absorption. Refer to the product packaging or prescribing information for the complete list of inactive ingredients.

Erdafixen (Erdafitinib) should only be used under the guidance of a qualified oncology specialist. The dosage is individualized based on clinical response, laboratory monitoring, serum phosphate levels, and treatment tolerance.

Recommended Adult Dose

• The usual starting dose is 8 mg orally once daily.
• Based on serum phosphate levels and clinical assessment, the dose may be increased to 9 mg once daily if appropriate.
• Continue treatment until disease progression or unacceptable toxicity occurs.

How to Take

• Swallow the tablet whole with water.
• Can be taken with or without food.
• Take the medicine at the same time each day.
• Do not crush, split, or chew the tablet unless advised by a healthcare professional.

Missed Dose

• If a dose is missed, take it as soon as you remember on the same day.
• If it is nearly time for the next scheduled dose, skip the missed dose and continue your regular schedule.
• Do not take two doses on the same day to make up for a missed dose.

Important Administration Advice

• Regular monitoring of serum phosphate levels, eye health, kidney function, and liver function may be required during treatment.
• Follow your oncologist's instructions regarding dose adjustments and scheduled laboratory tests.
• Do not stop or modify the treatment without consulting your healthcare provider.

Note: Dosage may vary depending on the patient's condition, laboratory findings, treatment response, and tolerability. Always follow the prescribing physician's recommendations.